By Julius Ewudo, Cyber Era NG ASEAN Region Representative
The agreement means Lenzetto® will now help address a critical shortage of Menopause Hormone Therapy (MHT) products in the Australian market
Specialty pharmaceuticals group Acrux Limited has announced the execution of an amendment to its licensing agreement for Lenzetto® with long-time partner Gedeon Richter Plc (Richter).
The amended agreement will see Acrux receive milestone payments from Richter for Lenzetto® in the Australian market. These milestone payments could total up to AUD 5.4 million, to be received within two years from launch and including an upfront payment and regulatory and commercial milestones.
Acrux-developed MHT product Lenzetto® already has a global footprint
Lenzetto® was developed by Acrux and is already licensed to and marketed by Gedeon Richter in more than 40 countries worldwide with sales of EUR 50 million in 2025. It is a transdermal Estradiol spray which is a hormone replacement therapy (HRT) treatment of symptoms associated with oestrogen deficiency occurring in women after menopause such as hot flushes.
Estradiol is delivered by the Company’s unique Patchless Patch™ delivery technology. This technology was invented at Monash University and has helped change the lives of women all over the world.
Acrux CEO and Managing Director, John Warmbrunn said: “The expansion of our existing licensing agreement with long-term partner Gedeon Richter paves the way for Acrux’s transdermal Estradiol spray Lenzetto® to deliver clear benefits to both Australian women and Acrux’s financials.
Getting this locally developed Estradiol spray into the hands of Australian women has been a key priority of ours for some time. The amended agreement with Richter means Australian women suffering oestrogen deficiency after menopause will soon have access to this hormone replacement therapy treatment,
From a financial performance angle, the extended agreement is set to deliver Acrux additional milestone payments of up to AUD5.4 million over the coming years. These payments place Acrux in a strong position as the Company continues to work towards bringing its innovative Female Testosterone product to market.”
Acrux Product Development and Technical Affairs Director, Felicia Colagrande said: “I am so delighted that Acrux has been able to get our Lenzetto®, Patchless Patch™ into Australia. It means Australian women will have a precise, consistent, discrete and easy to use option for their MHT.”
